A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients-Reference-Cited by-同舟云学术

A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients

Published:2024-05 Issue: Volume:174 Page:116537
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Rossi Sara^ORCID,Tatangelo Vanessa^ORCID,Dichiara Maria,Butini Stefania^ORCID,Gemma Sandra^ORCID,Brogi Simone,Pasquini Silvia^ORCID,Cappello Martina,Vincenzi Fabrizio^ORCID,Varani Katia^ORCID,Lopresti Ludovica^ORCID,Malchiodi Margherita,Carrara Chiara,Gozzetti Alessandro,Bocchia Monica,Marotta Giuseppe,Patrussi Laura,Carullo Gabriele^ORCID,Baldari Cosima T.,Campiani Giuseppe

Publisher

Elsevier BV

Reference30 articles.

1. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures;Hallek;Am. J. Hematol.,2021

2. Impact of fixed-duration oral targeted therapies on the economic burden of chronic lymphocytic leukemia in Canada;Lachaine;Curr. Oncol. 2023,2023

3. Genetics and epigenetics of CLL;Paul;Leuk. Lymphoma,2023

4. TP53 mutations in CLL: does frequency matter?;Al-Sawaf;Blood,2021

5. Expression in T-cells of the proapoptotic protein p66SHC is controlled by promoter demethylation;Pezzicoli;Biochem Biophys. Res. Commun.,2006

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies;ACS Pharmacology & Translational Science;2024-07-02